Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells
about
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerOncolytic virotherapy using herpes simplex virus: how far have we come?Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiformeICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.In vivo replication of an ICP34.5 second-site suppressor mutant following corneal infection correlates with in vitro regulation of eIF2 alpha phosphorylation.Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.Neutralizing innate host defenses to control viral translation in HSV-1 infected cells.Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Oncolytic viruses for cancer therapy II. Cell-internal factors for conditional growth in neoplastic cells.Designing Herpes Viruses as Oncolytics.Replication-competent herpes simplex vectors: design and applications.To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.Herpes simplex virus 1 (HSV-1) for cancer treatment.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus ImmunotherapyAn Engineered Herpesvirus Activates Dendritic Cells and Induces Protective Immunity.HSV Recombinant Vectors for Gene Therapy.Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response.Tinkering with translation: protein synthesis in virus-infected cells.Talimogene laherparepvec in the treatment of melanoma.A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.Shared ancestry of herpes simplex virus 1 strain Patton with recent clinical isolates from Asia and with strain KOS63.Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.
P2860
Q21132473-97799C0B-5E0F-4D5A-A8BE-4128BD72C5C9Q26862461-3F231123-BDDF-4529-AD76-1471027C8A1FQ33690926-AEA6B69D-0D59-4D83-88BB-6B691B6D9360Q34046125-4F6DE5AA-C4E2-4FE1-8C1B-A0BF3BE8FDA3Q34105106-B8BFFD9C-EFB4-4031-B34F-7E92DC2CB405Q34178661-451493D1-F62A-4B56-89B9-1583BC8566AEQ34858111-C1A5DBC2-615B-4997-9FA7-74E5A9658EBAQ35023693-FFF9E363-76A2-4B71-920A-D6A1CC97BBB3Q35116166-026F3884-2CA3-4CB2-B1B8-7AC2AC5AF0D3Q35385267-DA083A2B-49C1-4D66-81CC-2F591D0063E5Q35613824-B1197605-C1F7-46F4-A4CE-50BFD7A23816Q35635064-5C9CFD5B-A602-41B4-A435-94587E2CB1EDQ35867997-3FB526E1-9095-42B8-B97B-97A8CFF082EFQ36102568-79F7ADF6-3B37-4045-98C7-1FA0FFF97BBBQ36142487-07F96C53-6E96-412B-A8C5-470780FA3089Q36288909-96DEE20A-9C90-41E4-B428-06374722BE28Q36318160-66D34F17-C081-4FEC-84D9-2C9FEF301021Q36444443-9CB49AD7-68F9-4C2D-A78B-0812FEBC5A21Q36753953-08B72E38-089E-4782-8BF3-30196C6C4DB7Q37620494-78D1BE42-79D0-450F-8E74-FC1082B9E9C0Q37787777-BC4EB0A1-81C9-4E9A-B149-683F4F96D191Q37837495-0BA7E8B3-200B-4CA6-A196-4E024A16C09CQ37945174-CA9130A4-0C69-4D53-AA4E-FD272B273FD2Q38064834-461D8F2E-8FE6-45ED-AA67-D54C0F351DAFQ38656524-FF5A4590-8DC5-449C-82DE-35B58BDCF631Q40176322-81FC7B1B-E5FA-41E7-90DB-435786D446A8Q40286308-BAFA5D8D-4030-40F4-96D6-1DFD581FC2B1Q40373406-000C591B-9EEE-43FC-9442-6E52A9C468F7Q41928609-B91826A1-21CF-4F1D-BBB1-D405074F15CBQ55051893-9A4B6929-8237-4350-A838-CD2D7702DAEB
P2860
Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 July 2001
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhanced antitumor efficacy of ...... etic selection in cancer cells
@en
Enhanced antitumor efficacy of ...... tic selection in cancer cells.
@nl
type
label
Enhanced antitumor efficacy of ...... etic selection in cancer cells
@en
Enhanced antitumor efficacy of ...... tic selection in cancer cells.
@nl
prefLabel
Enhanced antitumor efficacy of ...... etic selection in cancer cells
@en
Enhanced antitumor efficacy of ...... tic selection in cancer cells.
@nl
P2093
P2860
P356
P1476
Enhanced antitumor efficacy of ...... etic selection in cancer cells
@en
P2093
P2860
P304
P356
10.1073/PNAS.161011798
P407
P577
2001-07-03T00:00:00Z